Mon, Sep 22, 2014, 7:20 PM EDT - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

Talon Therapeutics, Inc. Message Board

  • mattera mattera Jun 18, 2013 2:38 PM Flag

    IT's Looking Like July Will Be When The Fireworks Go Off

    I would estimate that MTL results and Talon's next steps will be revealed in July. The stock is simply moving/staying down due to people giving up and others capitalizing on their losses. Remember, Marqibo is still an approved cancer drug and MTL showing good Phase II results will significantly increase the value of Talon. It's all about timing. Hold on longs...

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • I am inclined to agree with you. The end of the second quarter is just 2 weeks away and if nothing transpires in July the second quarter report will be in August so we should at least have some feed back from Dr. Dietcher then about the MTL trial results.

      Remember, when Marqibo was going through the approval process and ODAC meetings - management was pretty transparent about events. Now we don't even know if they exist, everything is pretty tight which gives the impression that something is going on that warrants silence.

      GLTA

      • 1 Reply to bhakes_98
      • I agree that by Aug 15th something will have to be communicated.

        On another note, it's been close to 1 year since Marqibo has been approved. I have search FDA's web site and cannot find any regulation on how long a company can delay an approved drug being sold to its designated patient population. I sent a question to them, not identifying Talon or Marqibo, and am awaiting their response. I also sent the question into investor relations at Talon. Your thoughts?

 

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.